Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/05/20
End: 01/26/21
Due: 01/26/22
Phase: N/A
Priority: Normal
Start: 07/29/20
End: 05/10/22
Due: 05/10/23
Phase: N/A
Priority: Normal
Start: 01/13/23
End: 03/31/26
Due: 03/31/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease | NCT04382924 | Algernon Pharmaceuticals | user2@example.com | None | 2020-08-05 | 2021-01-26 | 2022-01-26 | - | - | 2025-07-14 |
| Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough | NCT04318704 | Algernon Pharmaceuticals | user2@example.com | None | 2020-07-29 | 2022-05-10 | 2023-05-10 | - | - | 2025-07-14 |
| Single and Repeat Doses of DMT in Healthy Subjects | NCT05559931 | Algernon Pharmaceuticals | user2@example.com | None | 2023-01-13 | 2026-03-31 | 2027-03-31 | - | - | 2025-07-14 |